UroGen Pharma Ltd. 4

Chief Medical Officer Mark Schoenberg had 1,667 RSUs convert into ordinary shares and sold 871 UroGen Pharma Ltd. (URGN) shares, mainly to cover tax withholding, in early September 2026.

On September 7, 2026, UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg settled 1,667 restricted stock units into an equivalent number of ordinary shares, increasing his direct holdings to 60,753 shares before any related sale. The following day, September 8, 2026, he sold 871 ordinary shares at an average price of $42.92 per share, a sale disclosed as being made to cover withholding tax obligations arising from the RSU settlement, reducing his direct holdings to 59,882 shares. The RSU transaction itself is a routine equity compensation vesting from a prior 5,000-share RSU grant made on September 7, 2023, scheduled to vest in three equal annual installments beginning September 7, 2024.

Filing Facts

CIK

1668243

Ticker

URGN

Form

4

Source Type

fda

Accession

0001437749-26-029965

Alert Tier

5